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Abstract
Colorectal cancer (CRC) is a multifactorial disease 
characterized by several genetic and epigenetic 
alterations occurring in epithelial cells. It is increasingly 
recognized that tumour progression is also regulated 
by tumour microenvironment (TME). The bidirectional 
cross-talk between tumour resident adipocytes and 
cancer cells within TME has been proposed as active 
contributor to carcinogenesis. Tumour resident adi-
pocytes exhibit an activated phenotype characterized 
by increased secretion of pro-tumorigenic factors 
(angiogenic/inflammatory/immune) which contribute 
to cancer cell proliferation, invasion, neoangiogenesis, 
evasion of immune surveillance and therapy resistance. 
Furthermore, adipocytes represent a fuel rich source 
for increasing energy demand of rapidly proliferating 
tumour cells. Interestingly, a relationship between 
obesity and molecular variants in CRC has recently 
been identified. Whether adipose tissue promotes 
cancer progression in subsets of molecular phenotypes 
or whether local tissue adipocytes are involved in 
inactivation of tumour suppressor genes and/or acti-
vation of oncogenes still needs to be explored. This 
editorial highlights the major findings related to cross-
talk between adipocytes and colon cancer cells and 
how local paracrine interactions may promote cancer 
progression. Furthermore, we provide future strategies 
in studying colonic TME which could provide insights in 
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bidirectional cross-talk mechanisms between adipocytes 
and colonic epithelial cells. This could enable to 
decipher critical signalling pathways of both early 
colonic carcinogenesis and cancer progression. 
Key words: Tumour resident adipocytes; Dysfunctional 
adipocytes; Adipose tissue; Cancer cell-tumour resident 
adipocyte cross-talk; Colon cancer microenvironment
© The Author(s) 2017. Published by Baishideng Publishing 
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Core tip: The tumor microenvironment (TME) has been 
implicated in cancer progression and chemoresistance. 
Adipocytes are active components of the TME. Bidire-
ctional cross-talk between adipocytes and cancer cells 
has recently been postulated to actively contribute to 
tumor initiation and progression. This Editorial highlights 
the role of local paracrine interactions between adi-
pocytes and colon cancer cells. Discovery of signalling 
pathways activated by tumor resident adipocytes in colon 
cancer will allow better understanding of carcinogenesis 
and provide potential therapeutic targets. 
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INTRODUCTION
Colorectal carcinogenesis is multifactorial involving 
interactions between genetic mutations (APC, TP53, 
PI3K, KRAS, BRAF, PTEN), microsatellite instability, 
chromosomal instability, epigenetic alterations 
(locus-specific CpG island methylation, global DNA 
hypomethylation)[1] and environmental factors 
(obesity, diabetes, metabolic syndrome, intestinal 
microbiome)[2]. Moreover the importance of “field 
cancerisation” has been highlighted in terms of cancer 
development in the macroscopically normal colon[3]. 
Epidemiologic studies support an association between 
high BMI and colorectal cancer (CRC) incidence and 
mortality[4]. Adipose tissue has been recognised as a 
major endocrine organ, secreting adipokines (leptin, 
adiponectin, visfatin), growth factors and immune/
inflammatory/angiogenic factors [tumour necrosis 
factor-alpha (TNF-α), interleukin-6 (IL-6), IL-8 and 
vascular-endothelial-growth-factor (VEGF)] involved 
in the regulation of systemic energy and metabolic 
homeostasis. Altered adipose tissue secretion of 
such factors has been implicated in dysregulation of 
inflammatory and immune responses leading not only 
to systemic low-grade inflammation and metabolic 
dysfunction, but also to local tissue inflammation 
contributing to cancer progression[5]. 
The tumour microenvironment (TME) comprising 
stromal cells (adipocytes, macrophages, fibroblasts, 
monocytes, neutrophils, infiltrating immune T-cells 
and B-cells) and extracellular matrix is a fertile soil 
for cancer cells. Increasing evidence suggests that 
paracrine bi-directional cancer cell-stromal cell cross-
talk is a key driver not only of local inflammation, but 
also activation and recruitment of immune cells, neo-
angiogenesis and extracellular matrix remodelling. This 
in turn contributes to cancer cell proliferation, invasion 
and migration[6]. 
This Editorial highlights the contribution of adipose 
tissue secreted factors in colon cancer progression with 
a focus on bidirectional cross-talk between adipocytes 
and colon cancer cells.
ANATOMIC AND MOLECULAR 
RELATIONSHIP BETWEEN ADIPOCYTES 
AND CRC
The mesentery, constituted by loose connective tissue 
and adipocytes, is the primitive envelope of the colon. 
Therefore, the colon lies in close proximity to adipose 
tissue depots. Submucosal distribution of adipocytes 
has also been reported[7], although the presence and 
proportion of submucosal fat in normal colonic wall is 
not well known. Increased submucosal fat deposition 
is a known characteristic of inflammatory bowel 
disease[8]. However, this has also been described in 
subjects without intestinal pathology[9]. Understanding 
normal colonic wall histology is essential in order 
to appreciate the close spatial relationship between 
adipocytes and colonic epithelial cells, progenitor cells 
of CRC.
Recently, an interesting area of research termed 
“molecular pathologic epidemiology” (MPE) has detected 
epigenetic modifications associated with obesity, 
providing insights into the relationship between obesity 
and molecular variants in CRC[10]. It has been proposed 
that microenvironment-derived signals trigger heritable 
genetic changes within cancer cells, contributing to 
tumour evolution[11]. Studies in breast cancer, suggest 
that bidirectional interactions induce sequential 
epigenetic modifications in both cancer and stromal 
cells with progression from in situ ductal carcinoma to 
invasive carcinoma[12]. Epigenetic modifications induced 
by tumour resident adipocytes in colon cancer cells 
have not been reported, although MPE studies have 
identified a relationship between obesity and molecular 
variants in CRC[10].
DYSFUNCTIONAL ADIPOCYTES AND 
CANCER
The main component of adipose tissue is white adipose 
tissue (WAT). Expansion of WAT is consequence of 
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an increase in size (hypertrophy) and/or increase 
in number (hyperplasia) of adipocytes. Healthy 
adipose tissue expansion consists in hypertrophic 
and hyperplastic white adipocytes, with appropriate 
angiogenic response, extracellular matrix remodelling 
and minimal inflammation. In contrast, pathological 
expansion of adipose tissue consists of adipocytes 
hypertrophy resulting in hypoxia, reduced angi-
ogenesis, infiltration of macrophages and immune 
cells, low-grade inflammation, excessive production 
of reactive oxygen radicals, endoplasmic reticulum 
stress, mithocondrial dysfunction and remodelling of 
extracellular matrix[13].
Inflammation is a recognised hallmark of cancer 
and pre-existing pro-inflammatory microenvironments 
are associated with increased cancer risk[14]. Increasing 
evidence, in breast, prostatic, ovarian and colon cancer, 
suggests that dysfunctional adipocytes are involved 
in cancer cell proliferation and migration through 
dysregulation of local and systemic inflammatory-
immune-angiogenic response system[15]. Inflammation 
is initiated by adipose tissue hypertrophy leading to 
localized hypoxia which activates hypoxia-inducible 
factor 1-alpha (HIF-1α). HIF-1α up-regulates secretion 
of chemokines and proangiogenic factors including 
TNF-α, IL-6, IL-1, monocyte chemoattractant protein 
(MCP-1), plasminogen activator inhibitor-1 and VEGF, 
which are involved in the recruitment of macrophages 
and initiation of angiogenesis. Recruited macrophages 
contribute further to up regulation of inflammatory/
immune cytokines favouring the acquisition of a sys-
temic and local inflammatory phenotype[16]. 
ROLE OF AT SECRETED FACTORS AND 
LIPID METABOLITES IN COLON CANCER
The adipose tissue secreted factors, lipid metabolites 
and signalling pathways have been summarized in 
Table 1.
TNF-α
TNF-α, secreted by dysfunctional adipose tissue, 
has been shown to support cancer cell proliferation, 
angiogenesis and metastasis through activation of 
key transcription factors, including PI3K/AKT/mTOR 
and nuclear transcription factor NF-κB[17-19]. TNF-α 
and hypoxic conditions also induce secretion of the 
proinflammatory cytokine IL-6, activator of Janus 
Kinase and signal transducers and activators of 
transcription 3 (Jak/STAT3) pathways, key regulators 
of cell proliferation and apoptosis[20].
Adipocyte secreted hormones, including leptin, 
adiponectin and visfatin, have also been implicated in 
colon cancer progression (Figure 1).
Leptin
Leptin is a potent inflammatory agent involved in up 
regulation of pro-inflammatory cytokines such as TNF-α, 
MCP-1, and reactive oxygen species from endothelial 
cells and peripheral blood mononuclear cells[21]. In vitro 
studies, in colon cancer cell lines, have demonstrated 
that leptin exerts pro-inflammatory, mitogenic, anti-
apoptotic and angiogenic properties[22,23]. 
Adiponectin
Adiponectin has a potent anti-inflammatory, anti-
proliferative and pro-apoptotic activity. However, 
proliferative and pro-inflammatory properties of 
adiponectin on colonic epithelial cancer cells have also 
been reported. Several studies suggest local-paracrine 
pro tumorigenic effects of adiponectin according to 
tissue-specific expression of its receptor subtypes 
(ADIPOR1 and ADIPOR2). Increased AdipoR1 and 
AdipoR2 expression has been associated with cancer 
progression linked with the pro-angiogenic activity of 
adiponectin[22,24]. 
Visfatin
Visfatin has been shown to exhibit pro-inflammatory 
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Table 1  Role of adipocyte secreted factors and metabolites and signalling pathways
AT secreted factors Function Signalling pathway Ref.
TNF-α Pro-inflammatory, PI3K, NF-κB Pikarsky et al[17], 2004
cell proliferation, anti-apoptotic, angiogenetic Huang et al[18], 2009
Viatour et al[19], 2005
IL-6 Pro-inflammatory, cell proliferation and anti- apoptotic JAK/STAT3 Hodge DR et al[20], 2005
Leptin Promotion of cell survival, proliferation, differentiation, 
pro-inflammatory
JAK/STAT, PI3K, MAPK Hefetz-Sela et al[22], 2013
Hoda et al[23], 2007
Adiponectin Anti-inflammatory, anti-proliferative and pro-apoptotic 
effect
Inhibition of PI3K, AMPK/mTOR, 
JAK/STAT3, NF-κB
Hefetz-Sela et al[22], 2013
Visfatin Pro-inflammatory, angiogenic, promotion of cell survival 
and migration
ERK/MAPK, PI3K/AKT, NF-κB, 
β1-integrin
Adya et al[25], 2008
Huang et al[26], 2013
Lipid peroxidation products Promotion of cell proliferation, differentiation, survival, 
migration, angiogenesis
PI3K/AKT/mTOR Ayala et al[27], 2014
NF-κB, PPAR, MAPK
PI3K: Phosphoinositide 3-kinase; NF-κB: Nuclear factor-kappa B; JAK/STAT3: Janus kinase/signal transducers and activators of transcription 3; MAPK: 
Mitogen-activated protein kinases; AMPK: AMP-activated protein kinase; mTOR: Mammalian target of rapamycin; HIF-1α: Hypoxia-inducible factor 
1-alpha; TNF-α: Tumor necrosis factor alpha; IL-6: Interleukin-6; AKT: Protein Kinase B; ERK: Extracellular signal-regulated kinase; PPAR: Peroxisome 
proliferator-activated receptors.
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signalling between tumour resident adipocytes and 
cancer cells. CRC progresses through sequential 
stages involving multiple layers of the colonic wall. 
TNM staging system is currently used for classifying 
CRC in 4 stages according to local invasion depth 
(T stage), lymph node involvement (N stage) and 
presence or absence of distant metastasis (M stage), 
providing indication for prognosis and therapeutic 
strategies. With cancer progression activation of 
complex signalling networks modify both cancer 
cells and stromal cells[28]. Cancer cells and activated 
stromal cells communicate by autocrine/paracrine 
pathways contributing to dynamic modulation of TME 
through persistent recruitment of inflammatory and 
stromal cells in the TME. As a result, TME becomes 
increasingly populated with infiltrating innate immune 
cells (macrophages, neutrophils), adaptive immune 
cells (T and B lymphocytes) pericytes and stem cells 
contributing to cancer cell proliferation and invasion 
(Figure 2). 
Adipocytes located in close proximity to tumour 
invasive front are reprogrammed by cancer cells 
into activated fibroblast-like cells. Tumour resident 
adipocytes exhibit morphological and functional 
modifications, known as adipocyte dedifferentiation, 
consisting in size reduction, due to enhanced lipolytic 
and pro-angiogenic effects in endothelial cells[25]. 
Studies have demonstrated a role of visfatin in CRC. 
CRC cells express chemokine receptors (CXCR4 and 
CXCR7), activated by visfatin, which bind stromal cell-
derived factor-1, promoter of survival and migration of 
cancerous cells[26].
Lipid peroxidation products
The chronic low-grade inflammatory state of 
dysfunctional adipocytes leads to activation of lipid 
peroxidation with the production and secretion of 
4-hydroxy-2-nonenal (4-HNE) and malondialdehyde. 
The secreted 4-HNE is responsible of deregulation of 
multiple pathways involved in tumour cell proliferation, 
differentiation, cell survival, migration, apoptosis and 
angiogenesis including MAPK, PI3K-AKT-mTOR, NF-κB. 
This also results in upregulation of prostaglandin E2 
(PGE2) and cyclooxygense-2, implicated in CRC[27]. 
ACTIVATED PHENOTYPE OF TUMOUR 
RESIDENT ADIPOCYTES AND LOCAL 
PARACRINE REGULATION OF COLON 
CANCER
Recently great interest has emerged in reciprocal 
Figure 1  Signalling pathways activated by tumour resident adipocytes secreted factors. Tumour resident adipocytes secreted factors activate cell cycle 
regulators and inflammatory/immune/angiogenic regulators. Cancer cell secreted inflammatory cytokines activate host cells of TME constituting a paracrine/autocrine 
loop. MAPK: Mitogen-activated protein kinases; PI3K: Phosphoinositide 3-kinase; AKT: Protein Kinase B; mTOR: Mammalian target of rapamycin; NF-κB: Nuclear 
factor-κB; JAK/STAT3: Janus kinase/signal transducers and activators of transcription 3; HIF-1α: Hypoxia-inducible factor 1-alpha; TNF-α: Tumor necrosis factor 
alpha; IL-6: Interleukin-6.
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activity, decreased adipocyte-differentiation markers 
(adiponectin, resistin, fatty acid binding protein-4, 
adipocyte protein 2), and increased secretion of 
inflammatory factors (IL-6, IL-8, IL-1 β, TNF-α), growth 
factors (insulin-like growth factor 1, IGF1 binding 
proteins), angiogenic factors (VEGF) and MCP-1 
(CCL2)[15]. In vitro studies, in breast and prostate 
cancer, have demonstrated that tumour resident 
adipocyte secreted factors activate signalling pathways 
involved in cancer cell survival, proliferation, invasion, 
epithelial to mesenchimal transition, angiogenesis 
and extracellular matrix remodelling, promoting cancer 
initiation and metastasis[15,22]. Active recruitment of 
adipocytes to TME has not been reported, although 
it has been reported that bone marrow derived 
mesenchymal stem cells (progenitors of adipocytes) 
may be recruited to specific sites of neoplasia inducing 
metastatic properties[29]. An open question is whether 
adipose tissue promotes cancer progression in subsets 
of molecular phenotypes or whether local tissue 
adipocytes are involved in inactivation of tumour 
suppressor genes and/or activation of oncogenes 
(Figure 3). 
Adipocytes serve as a fuel rich source for increasing 
energy demand of rapidly proliferating tumour cells. 
Advanced stages of gastrointestinal malignancies 
often present with cancer-associated-cachexia as 
a result of lipolysis induced by cancer cells. Studies 
have described increased lipid droplets in colon 
adenocarcinoma and it has been implicated in PGE2 
synthesis. Inhibition of lipid droplet formation by fatty 
acid synthase inhibitors reduces cancer cell proliferation 
in vitro, suggesting a role of lipid droplets in colon 
adenocarcinoma[30]. 
Metabolic and transcriptomic expression profile and 
direct paracrine effects of tumour resident adipocytes 
in colon cancer have not been evaluated. We have 
preliminary data (unpublished) indicating increased 
expression of pro-inflammatory/immune/angiogenic 
factors in colon cancer resident adipocytes, isolated 
from paraffin embedded sections using laser micro 
dissection system, compared to adipocytes isolated 
from the distal non neoplastic mucosa.
TME signalling pathways have recently been 
implicated in inducing chemoresistance in breast and 
prostate cancer[31]. There is also evidence, in colon 
cancer cell lines, that leptin inhibits cytotoxic effects of 
5-fluorouracil[32].
Novel strategies in studying TME
Two dimensional (2D) cell culture models, widely 
used in basic science research, do not reproduce 
the complex interactions between host cells of 
TME. Recently, three-dimensional (3D) organoid 
models, derived from mouse and human intestinal 
tissue ex vivo, have been described. These in vitro 
organ-like cultures reproduce intestinal tissue micro-
environment. Furthermore, they can be co-cultured 
with stromal components[33]. Reproduction of colonic 
microenvironment in vitro will allow to decipher ex 
vivo bidirectional cross-talk mechanisms between 
adipocytes and colonic epithelial cells.
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Figure 2  Colon cancer progression and tumour microenvironment. Bi-directional cross-talk between host cells of tumour microenvironment (TME) contributes 
to colon cancer progression. Activated tumour resident adipocytes increase secretion of cytokines, growth factors, adipokines and release lipid metabolites promoting 
colon cancer cell proliferation and migration. Cancer cells secrete inflammatory factors which repopulate TME, further enhancing cancer cell proliferation. Tis: 
carcinoma in situ; T1: Tumour invades submucosa; T2: Tumour invades muscularis propria; T3: Tumour invades through muscularis propria into pericolorectal tissues; 
T4a: Tumour penetrates to the surface of the visceral peritoneum; T4b: Tumour directly invades or is adherent to other organs or structures. 
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CONCLUSION
The bidirectional cross talk between tumour resident 
adipocytes and colon cancer cells contributes to the 
progressive evolution of tumour microenvironment 
and cancer progression. It is therefore important to 
decipher the metabolic and transcriptomic expression 
profiles of colon cancer resident adipocytes in different 
stages of tumour progression. Colon organoid cultures 
combined with adipocytes and/or tumour resident 
adipocyte secreted factors will allow to identify critical 
signalling pathways of both early colonic carcino-
genesis and cancer progression providing diagnostic 
biomarkers and novel therapeutic targets for colon 
cancer.
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